254 related articles for article (PubMed ID: 33516741)
1. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature.
Natale C; Carlos C; Hong J; Khera M; Baum N; Raheem OA
Sex Med Rev; 2021 Jul; 9(3):393-405. PubMed ID: 33516741
[TBL] [Abstract][Full Text] [Related]
2. The Role of Testosterone Therapy in the Setting of Prostate Cancer.
Rodriguez KM; Pastuszak AW; Khera M
Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247
[TBL] [Abstract][Full Text] [Related]
3. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
Chen T; Li S; Eisenberg ML
J Sex Med; 2021 Aug; 18(8):1346-1353. PubMed ID: 34303630
[TBL] [Abstract][Full Text] [Related]
4. Testosterone therapy in prostate cancer: is it still a controversy?
Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
[TBL] [Abstract][Full Text] [Related]
6. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
Kaufman JM; Graydon RJ
J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
[TBL] [Abstract][Full Text] [Related]
7. Controversies in Testosterone Therapy.
Twitchell DK; Pastuszak AW; Khera M
Sex Med Rev; 2021 Jan; 9(1):149-159. PubMed ID: 33309270
[TBL] [Abstract][Full Text] [Related]
8. Testosterone Therapy Among Prostate Cancer Survivors.
Nguyen TM; Pastuszak AW
Sex Med Rev; 2016 Oct; 4(4):376-88. PubMed ID: 27474995
[TBL] [Abstract][Full Text] [Related]
9. Safety of testosterone therapy in men with prostate cancer.
Morgentaler A; Caliber M
Expert Opin Drug Saf; 2019 Nov; 18(11):1065-1076. PubMed ID: 31495240
[No Abstract] [Full Text] [Related]
10. Controversies with testosterone therapy.
Khera M
Can J Urol; 2020 Aug; 27(S3):20-23. PubMed ID: 32875998
[TBL] [Abstract][Full Text] [Related]
11. Current state of practice regarding testosterone supplementation therapy in men with prostate cancer.
Kovac JR; Pan MM; Lipshultz LI; Lamb DJ
Steroids; 2014 Nov; 89():27-32. PubMed ID: 25072793
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Saad F; Caliber M; Doros G; Haider KS; Haider A
Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
[No Abstract] [Full Text] [Related]
13. Is testosterone a friend or a foe of the prostate?
Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
[TBL] [Abstract][Full Text] [Related]
15. Use of testosterone replacement therapy in patients with prostate cancer.
Dorff TB; Vogelzang NJ
Curr Urol Rep; 2011 Jun; 12(3):223-8. PubMed ID: 21365235
[TBL] [Abstract][Full Text] [Related]
16. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
17. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
18. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine.
Morgentaler A; Traish A; Hackett G; Jones TH; Ramasamy R
Sex Med Rev; 2019 Oct; 7(4):636-649. PubMed ID: 31351915
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.
Kaplan AL; Trinh QD; Sun M; Carter SC; Nguyen PL; Shih YT; Marks LS; Hu JC
J Sex Med; 2014 Apr; 11(4):1063-1070. PubMed ID: 24443943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
